Skip to main content
. 2021 May 28;8:685746. doi: 10.3389/fcvm.2021.685746

Table 2.

Baseline characteristics of patients.

Studies Patients (n) Age (years) Female (%) DM (%) MR (%) MS (%) MR+MS (%) AF (%) CS AVR (%) CS TVP (%)
MVP MVR MVP MVR MVP MVR MVP MVR MVP MVR MVP MVR MVP MVR MVP MVR MVP MVR MVP MVR
Brescia 2020 80 100 NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA
Chen 2020 467 467 56.8 ± 14.2 56.7 ± 13.8 53.1 55.9 14.6 16.5 19.3 18.8 65.1 65.5 15.6 15.6 57.4 58.0 22.1 21.0 26.3 27.2
Fu 2020 529 529 54.5 ± 10.9 54.6 ± 10.0 72.2 72.2 10.0 13.0 12.7 10.2 10.4 11.9 76.9 77.9 67.9 69.6 18.9 19.8 91.1 89.2
Kim 2018 188 188 48.8 ± 3.4 47.6 ± 2.1 71.8 75.5 11.7 13.8 50.5 47.3 30.3 33.0 19.1 19.7 64.9 63.8 23.4 20.2 38.3 35.6
Russell 2017 119 1078 57.3 62.0 58.0 73.1 14.3 21.1 81.5 63.9 25.2 75.3 NA NA 26.1 48.9 NA NA NA NA
Geldenhuys 2012 69 69 36.9 ± 14.5 40.9 ± 11.7 78.3 84.1 NA NA 39.0 13.0 3.0 7.0 27.0 49.0 29.0 39.0 NA NA 6.0 13.0
Wang 2008 33 59 49.7 ± 13.2 58.1 ± 11.2 63.7 66.1 12.1 6.8 NA NA NA NA NA NA 93.9 96.6 NA NA 45.5 61.0
Kuwaki 2007 47 81 48.0 ± 10.0 53.0 ± 8.0 70.2 58.0 2.1 7.4 8.5 6.2 83.0 54.3 8.5 39.5 NA NA 100 100 17.0 40.7
Talwar 2007 76 293 30.3 ± 10.4 32.5 ± 10.7 30.3 27.8 NA NA 15.8 13.2 40.8 44.4 43.4 42.4 48.7 38.3 100 100 NA NA
Ho 2004 201 408 32.2 ± 10.4 38.7 ± 8.6 46.3 44.4 NA NA 37.4 12.7 30.3 59.1 32.3 28.2 36.8 60.3 100 100 28.9 32.4
Yau 2000 142 431 42.0 ± 13.1 57.9 85.0 79.6 NA NA 16.2 14.8 67.6 48.0 16.2 37.1 NA NA NA NA 7.8 17.6

MVP, mitral valve repair; MVR, mitral valve replacement; NA, not available; DM, diabetes mellitus; MR, mitral regurgitation; MS, mitral stenosis; AF, atrial fibrillation; CS, concomitant surgery; AVR, aortic valve replacement; TVP, tricuspid valve repair (13, 1524).